PL2111868T3 - Zastosowanie ludzkiej albuminy do wytwarzania leku do leczenia pacjentów cierpiących na zaburzenia funkcji poznawczych - Google Patents

Zastosowanie ludzkiej albuminy do wytwarzania leku do leczenia pacjentów cierpiących na zaburzenia funkcji poznawczych

Info

Publication number
PL2111868T3
PL2111868T3 PL08380301T PL08380301T PL2111868T3 PL 2111868 T3 PL2111868 T3 PL 2111868T3 PL 08380301 T PL08380301 T PL 08380301T PL 08380301 T PL08380301 T PL 08380301T PL 2111868 T3 PL2111868 T3 PL 2111868T3
Authority
PL
Poland
Prior art keywords
drug
preparation
treatment
patients suffering
human albumin
Prior art date
Application number
PL08380301T
Other languages
English (en)
Inventor
Roura Victor Grifols
Original Assignee
Grifols Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Sa filed Critical Grifols Sa
Publication of PL2111868T3 publication Critical patent/PL2111868T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL08380301T 2007-10-26 2008-10-22 Zastosowanie ludzkiej albuminy do wytwarzania leku do leczenia pacjentów cierpiących na zaburzenia funkcji poznawczych PL2111868T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200702831A ES2332846B1 (es) 2007-10-26 2007-10-26 Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos.
EP08380301.5A EP2111868B1 (en) 2007-10-26 2008-10-22 Use of therapeutic human albumin for the preparation of a drug for the treatment of patients suffering from cognitive disorders

Publications (1)

Publication Number Publication Date
PL2111868T3 true PL2111868T3 (pl) 2014-01-31

Family

ID=40583637

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08380301T PL2111868T3 (pl) 2007-10-26 2008-10-22 Zastosowanie ludzkiej albuminy do wytwarzania leku do leczenia pacjentów cierpiących na zaburzenia funkcji poznawczych

Country Status (16)

Country Link
US (1) US7851446B2 (pl)
EP (1) EP2111868B1 (pl)
JP (1) JP5437619B2 (pl)
CN (1) CN101417123B (pl)
AR (1) AR068901A1 (pl)
AU (1) AU2008233025B8 (pl)
BR (1) BRPI0804623B8 (pl)
CA (1) CA2641830C (pl)
CL (1) CL2008003133A1 (pl)
ES (2) ES2332846B1 (pl)
MX (1) MX2008013635A (pl)
NZ (1) NZ572131A (pl)
PL (1) PL2111868T3 (pl)
PT (1) PT2111868E (pl)
RU (1) RU2414925C2 (pl)
UY (1) UY31418A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10112000B2 (en) 2010-07-08 2018-10-30 Asahi Kasei Medical Co., Ltd. Method for reducing amyloid beta concentration in blood
LT3484502T (lt) * 2016-08-18 2021-12-10 Alkahest, Inc. Kraujo plazmos frakcijos, kaip su senėjimu susijusio pažinimo sutrikimo gydymo priemonė
EA039316B1 (ru) * 2016-10-24 2022-01-12 Алкахест, Инк. Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением
US11040068B2 (en) 2017-04-26 2021-06-22 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
MX2019012795A (es) * 2017-04-26 2020-02-13 Alkahest Inc Régimen de dosificación para el tratamiento de deterioros cognitivos y motores con plasma de sangre y productos de plasma de sangre.
SG11202100347QA (en) * 2018-07-20 2021-02-25 Alkahest Inc Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
EP3643319A1 (en) * 2018-10-25 2020-04-29 Grifols Worldwide Operations Limited Use of low volume plasma exchange for the treatment of alzheimer's disease in early and middle stages
SG11202103696XA (en) 2018-10-26 2021-05-28 Alkahest Inc Use of plasma and plasma fractions for improvement of pain, wound healing, and postoperative recovery
CA3200309A1 (en) * 2020-10-30 2022-05-05 Shenzhen Protgen Ltd. Use of human serum albumin in treatment of diseases
UY39742A (es) * 2021-04-30 2022-11-30 Grifols Worldwide Operations Ltd Uso de recambio plasmatico terapeutico y recambio plasmatico de bajo volumen para el tratamiento *
WO2025230830A1 (en) 2024-04-29 2025-11-06 Alkahest, Inc. Compositions of blood plasma fractions and their use in treatment of spinal muscular atrophy (sma)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3612137A1 (de) * 1986-04-10 1987-10-15 Biotest Pharma Gmbh Steriles plasmaaustauschmittel
US5112298A (en) 1990-06-25 1992-05-12 Baxter International Inc. Apheresis method and device
US5178603A (en) 1990-07-24 1993-01-12 Baxter International, Inc. Blood extraction and reinfusion flow control system and method
US6627151B1 (en) * 1997-06-13 2003-09-30 Helmut Borberg Method for treatment diseases associated with a deterioration of the macrocirculation, microcirculation and organ perfusion
ATE312354T1 (de) 2000-05-23 2005-12-15 Univ Southern California Diagnose von alzheimerkrankheit unter verwendung von ldl-rezeptor-protein-1
EP1370240A4 (en) * 2001-03-02 2004-09-22 Neuron Therapeutics Inc NEUROPROTECTOR FORMULATIONS AND METHOD
WO2003051374A2 (en) 2001-12-17 2003-06-26 New York State Office Of Mental Health SEQUESTRATION OF Aβ IN THE PERIPHERY IN THE ABSENCE OF IMMUNOMODULATING AGENT AS A THERAPEUTIC APPROACH FOR THE TREATMENT OR PREVENTION OF BETA-AMYLOID RELATED DISEASES
JP4690043B2 (ja) 2002-10-04 2011-06-01 プラナ バイオテクノロジー リミティッド 神経に対し活性な化合物
AU2003303198A1 (en) * 2002-12-19 2004-07-14 New York University Method for treating amyloid disease
CN100384471C (zh) 2003-02-13 2008-04-30 奥克塔法马股份有限公司 白蛋白溶液及其制备方法
KR20060040676A (ko) 2003-07-11 2006-05-10 미리어드 제네틱스, 인크. 알츠하이머병을 치료하기 위한 약제학적 방법, 투약 방법및 제형
AT413336B (de) * 2003-09-12 2006-02-15 Mattner Frank Dr Apherese-vorrichtung
US20050182044A1 (en) 2004-02-17 2005-08-18 Bruinsma Gosse B. Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate
AT500483B1 (de) 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
RU2281090C2 (ru) * 2004-09-23 2006-08-10 Алексей Владимирович Смирнов Способ лечения больных хронической почечной недостаточностью
RU2261702C1 (ru) * 2004-09-23 2005-10-10 Смирнов Алексей Владимирович Способ лечения гипергомоцистеинемии у больных с хронической почечной недостаточностью, получающих лечение гемодиализом или гемофильтрацией
US7436304B1 (en) 2005-07-19 2008-10-14 Visible Assets, Inc Evidence tracking

Also Published As

Publication number Publication date
RU2414925C2 (ru) 2011-03-27
BRPI0804623B8 (pt) 2021-05-25
AU2008233025B8 (en) 2013-07-25
PT2111868E (pt) 2013-10-17
US7851446B2 (en) 2010-12-14
CL2008003133A1 (es) 2009-08-07
CA2641830A1 (en) 2009-04-26
CN101417123A (zh) 2009-04-29
BRPI0804623B1 (pt) 2020-02-11
MX2008013635A (es) 2009-05-11
UY31418A1 (es) 2009-05-29
AU2008233025A1 (en) 2009-05-14
US20090111740A1 (en) 2009-04-30
CA2641830C (en) 2013-07-16
AU2008233025B2 (en) 2013-06-27
CN101417123B (zh) 2012-06-27
JP5437619B2 (ja) 2014-03-12
EP2111868A1 (en) 2009-10-28
ES2332846B1 (es) 2010-07-08
HK1126689A1 (en) 2009-09-11
ES2428698T3 (es) 2013-11-08
ES2332846A1 (es) 2010-02-12
BRPI0804623A2 (pt) 2009-06-30
NZ572131A (en) 2010-06-25
AR068901A1 (es) 2009-12-16
EP2111868B1 (en) 2013-08-21
JP2009108059A (ja) 2009-05-21
RU2008141076A (ru) 2010-04-27

Similar Documents

Publication Publication Date Title
PL2111868T3 (pl) Zastosowanie ludzkiej albuminy do wytwarzania leku do leczenia pacjentów cierpiących na zaburzenia funkcji poznawczych
EP2166837A4 (en) DRUG COMBINATION USEFUL FOR THE TREATMENT OF SKIN DISORDERS
IL217901B (en) Use of laquinimod or a laquinimod salt in the manufacture of a drug for the treatment of bdnf-related diseases
HUS1500058I1 (hu) Benzoxazint tartalmazó gyógyszer-kombináció légúti betegségek kezelésére
IL202515A (en) Thyroid-like compounds and their use in the preparation of drugs for the treatment of @ metabolic diseases
IL188204A0 (en) Combination therapy for the treatment of immunoinflammatory disorders
IL213407A (en) Use of combinations of drug factors to prepare combination therapy drugs
IL184425A0 (en) Cxcr4 antagonists for the treatment of medical disorders
AP2037A (en) Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
IL182105A0 (en) Use of memantine for the preparation of a medicament for the treatment of childhood behavioral disorders
ZA200703601B (en) Medicaments for the treatment or prevention of fibriotic diseases
SG10201912182UA (en) Improved modalities for the treatment of degenerative diseases of the retina
PL378108A1 (pl) Leczenie łączone do terapii zapalnych zaburzeń immunologicznych
IL261742B (en) Human antibodies and their diagnostic and therapeutic uses for the treatment of neurological diseases
EP2306824A4 (en) IONTOPHORETIC DELIVERY OF CURCUMINE AND CURCUMINANALOGUE FOR THE TREATMENT OF MORBUS ALZHEIMER
PL1670482T3 (pl) Zastosowanie cyklezonidu w leczeniu chorób układu oddechowego
PL1940409T3 (pl) Nowe kombinacje leków do leczenia chorób dróg oddechowych
ZA200607531B (en) Use of agomelatine in obtaining medicaments intended for the treatment of sleep disorders in the depressed patient
IL206435A0 (en) Therapeutic regimens for the treatment of immunoinflammatory disorders
TWI369988B (en) New pharmaceutically active compounds for the treatment of respiratory diseases
EP1838316A4 (en) MACROCYCLIC ANALOGUES USEFUL FOR THE TREATMENT OF IMMUNOREGULATION DISORDERS AND RESPIRATORY DISEASES
EP2203174A4 (en) THERAPEUTIC REGIMES FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS
ZA200505996B (en) Combination therapy for the treatment of immunoinflammatory disorders
IL207977A0 (en) Therapy for disorders of the proximal digestive tract
SI2344166T1 (sl) Farmacevtska sestava za zdravljenje gastrointestinalnih iritacij